Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Cohort studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie· Jul 2026

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou, Mingming Yang, Jing Zhang … Koju Kamoi

Read paper

RetinaCohort studyTreatmentQ1IF 3.1

Adding a steroid injection to adalimumab was linked to faster improvement in uveitic macular edema.

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou … Koju Kamoi

Graefe's archive for clinical and experimental ophthalmology · Jul 2026 · Q1 in Ophthalmology

Background

Noninfectious uveitic macular edema (uveitic macular edema) is a major cause of visual impairment and remains challenging in refractory cases.

Purpose

This study compared adalimumab monotherapy with adalimumab combined with sub-Tenon's triamcinolone acetonide (STTA) bridging therapy in refractory noninfectious uveitic macular edema.

Methods

In this retrospective longitudinal cohort study, 30 patients (44 eyes) with refractory noninfectious uveitic macular edema treated with adalimumab (2015-2025) were included.

n = 44 eyes

Results

adding the steroid shot sped up eye swelling improvement compared with adalimumab alone

HR by subgroup · 95% CI

More results

Adjusted analyses showed greater visual improvement in the bridging group at 12 months (difference 0.307 LogMAR; p < 0.001) and at 15, 24, and 36 months (p < 0.05).

Greater central subfield thickness reductions were observed at 3, 18, 21, and 36 months (p < 0.05).

More results

Relapse risk did not differ significantly (HR 0.711, 95% CI 0.155-3.272; p = 0.662).

IOP changes were generally comparable.

“

Conclusion

Adalimumab combined with STTA bridging therapy was associated with earlier anatomical improvement and additional visual benefits compared with adalimumab monotherapy, without increased relapse risk.

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Related papers